No Data
No Data
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
BofA Securities Maintains Zai Lab(ZLAB.US) With Hold Rating, Maintains Target Price $36.1
ZAI LAB (09688.HK) plans to hold a Board of Directors meeting on May 8 to approve the first-quarter performance.
Gelonghui reported on April 24 that ZAI LAB (09688.HK) announced that the Board of Directors' Audit Committee will review and approve on May 8, 2025 (Thursday) the company's and its subsidiaries' unaudited quarterly performance for the three months ending March 31, 2025, prepared in accordance with US Generally Accepted Accounting Principles and applicable rules of the USA Securities and Exchange Commission ("first quarter performance") and its release.
Zai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting
Asian Equities Traded in the US as American Depositary Receipts Surge in Tuesday Trading
ZAI LAB (09688) issued 2 million new shares on April 22.
ZAI LAB (09688) announced that on April 22, 2025, it will execute in accordance with the previously disclosed terms (1)...